Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eosinophilic Esophagitis in PPI-Refractory Heartburn
NCT01404832Phase 4Terminated
- Sponsor
- Dallas VA Medical Center
- Start
- Oct 2007
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lansoprazole in gastroesophageal reflux disease (GERD), sponsored by Dallas VA Medical Center. Primary endpoint: Number of Participants With Eosinophilic Esophagitis at 8 weeks. Started Oct 2007; status: terminated.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01404832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01404832.